A TECHNOLOGY PLATFORM FOR TRANSLATION OF ATMPS (ADVANCED THERAPY MEDICINAL PRODUCTS): THE EXAMPLE OF HUMAN EYE AND SKIN
G. Pellegrini | Head of Cell Therapy Program Center for Regenerative Medicine Department of Life Sciences University of Modena e Reggio Emilia, Modena, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Developing cellular therapies is not straightforward. This presentation summarizes the experience of academic stem cell investigators working in different clinical applications and aiming to share insight into what could be useful to consider, in light of the current situation regarding advanced therapies. These include 1) choosing the stem cell type and assessing a platform of technologies possibly common to multiple products, 2) familiarity with GMP manufacturing, reagent validation, and supply chain management, 3) product delivery issues and the additional regulatory challenges, 4) the relationship between clinical trial design and preclinical studies, and 5) the market approval requirements, scalability, pathways, and partnerships needed.
Downloads
Citations
Supporting Agencies
-Data Availability Statement
OAHow to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
